US Drug Patent 9,629,821: Scope, Claims, and US Landscape for Fish-Oil Lipid Emulsion to Prevent PNALD
What does US 9,629,821 claim, in practical terms?
US 9,629,821 claims prevention of parenteral nutrition associated liver disease (PNALD) by giving a fish-oil-derived omega-3 fatty acid lipid emulsion by intravenous administration to patients receiving long-term total parenteral nutrition (PN). The method is constrained by two core negatives:
1) The lipid emulsion does not contain phytosterols or plant-derived fatty acids.
2) The patient is not administered phytosterols or plant-derived fatty acids.
The claims are written as method-of-prevention claims, not composition claims.
Independent claim 1: key scope elements
Claim 1 is the foundational independent claim. It has a structured set of requirements that together define infringement risk and competitive design-around space.
Claim 1 elements
- Indication/endpoint: preventing PNALD in a human patient
- Care setting: patient is obtaining nutritional support through total parenteral nutrition (PN)
- Route: intravenous administration
- Active ingredient: a lipid emulsion comprising fish oil derived omega-3-fatty acid
- Negative composition limitation: emulsion does not contain phytosterols or plant derived fatty acids
- Negative patient limitation: patient is not administered phytosterols or plant derived fatty acids
- Duration framing: “long-term nutritional support” through parenteral nutrition (without a single numeric cutoff in claim 1)
Immediate business read
- The claim is intended to capture omega-3 fish-oil emulsions used in PN regimens where the rest of the nutritional plan avoids phytosterol exposure and plant fatty acids (commonly associated with soy- and plant-derived PN lipid sources).
Dependent claims: where the scope narrows
Dependent claims specify liver disease subtype, fish sources, emulsifier systems, patient subpopulations, dosing windows, and treatment duration.
Disease subtype and patient class
- Claim 2: PNALD is fatty liver disease
- Claim 5-7: patient types
- Claim 5: newborn
- Claim 6: premature newborn
- Claim 7: infant
- Claim 8-9: pediatric bands
- Claim 8: child under 18
- Claim 9: child under 12
- Claim 10: adult receiving long term PN
- Claim 16: a distinct pediatric method for patients under 2 years old with short-bowel syndrome, receiving nutrition solely through PN
Fish-oil raw material constraints
- Claim 3: fish source is limited to one of:
- menhaden, herring, mackerel, cod, caplin, tilapia, tuna, sardine, pacific saury, salmon, arctic char, or krill
Emulsion preparation/emulsifier limitation
- Claim 4: emulsion is prepared using emulsifying agent selected from:
- egg phosphatidylcholine, egg lecithin, L-a-dipalmitoyl phosphatidylcholine (DPPC), DL-a-dipalmitoyl phosphatidylethanolamine (DPPE), dioleoyl phosphatidylcholine (DOPC)
Dosing windows
- Claim 12: omega-3-fatty acid dose: 0.2 g/kg/day to 3.0 g/kg/day
- Claim 13: narrower dose: 0.5 g/kg/day to 1.0 g/kg/day
Treatment duration
- Claim 17: administration period greater than 3 weeks
- Claim 18: administration period greater than 6 weeks
- Claim 19: administration period greater than 3 months
Clinical risk population
- Claim 14: patient has short-bowel syndrome
- Claim 16: combines (i) under-2, (ii) nutrition solely via PN, and (iii) short-bowel syndrome.
How broad is the claim set?
The patent is broad on the axis of therapeutic concept (prevent PNALD using fish-oil omega-3 lipid emulsions) but narrow on manufacturability and regimen composition via two negative limitations (no phytosterols/plant-derived fatty acids) and several structural constraints (fish sources and specific emulsifiers in dependent claims).
Scope matrix (what is in vs out)
| Dimension |
What the claims capture |
What creates potential design-around |
| Active ingredient |
Fish oil derived omega-3 fatty acid |
Non-fish sources of omega-3 or different actives |
| Emulsion composition |
Emulsion excludes phytosterols and plant-derived fatty acids |
Include phytosterols or plant-derived fatty acids in emulsion |
| Patient exposure |
Patient is not administered phytosterols or plant-derived fatty acids |
Use concomitant PN components containing phytosterols/plant fatty acids |
| Formulation manufacturing |
Dependent claims limit emulsifier options |
Use emulsifiers outside the listed set (but note claim 1 may still be implicated) |
| Fish raw material |
Dependent claim 3 enumerates fish sources |
Use fish oil derived from other marine sources (unless still “fish oil derived omega-3” is interpreted broadly under claim 1) |
| Indication |
PNALD prevention |
Treatment after PNALD onset could fall outside “preventing” framing |
| Duration |
Dependent claims add time thresholds |
Shorter-than-threshold prophylaxis periods |
Core claim risk profile for competitors
For infringement risk, claim 1 is the anchor. Even if competitors avoid specific emulsifier or fish source limitations, they must still avoid:
1) Using a fish-oil-derived omega-3 lipid emulsion in PN regimens intended to prevent PNALD, and
2) Ensuring the regimen is consistent with the “no phytosterols or plant-derived fatty acids” negative limitations both in the emulsion and in patient administration.
This produces two practical exposure channels:
- Direct exposure: The competitor markets/uses a fish-oil omega-3 lipid emulsion for PNALD prevention in patients on total PN while the overall PN regimen avoids phytosterols/plant fatty acids.
- Method-of-use evidence exposure: Even if the product is compositionally close, claim language ties to prevention in human patients receiving long-term PN. Clinical protocols, IFU language, training materials, and investigator protocols can matter to the “method” analysis.
Where claim 16 sits in the hierarchy
Claim 16 is a narrower “stacked” dependent claim that materially increases proof burden but also targets a commercially relevant niche: infants <2 years with short-bowel syndrome on nutrition solely through PN, again with the phytosterol/plant fatty acid exclusions.
Claim 16 additional limitations vs claim 1
- Patient: <2 years
- Nutrition: “solely through PN”
- Condition: short-bowel syndrome
- Repeats: fish-oil omega-3 emulsion, no phytosterols/plant-derived fatty acids in emulsion, and patient not administered such components.
What does the negative limitation do to patent scope?
The two negative limitations are the patent’s main differentiators versus many PN lipid products and regimens.
Negative limitation A: emulsion exclusion
Claim 1 requires the administered lipid emulsion to not contain phytosterols or plant-derived fatty acids.
Negative limitation B: patient exclusion
Claim 1 also requires the patient is not administered phytosterols or plant-derived fatty acids.
Implication for regimen design
- Even if a competitor’s emulsion has low phytosterol content, the method claim can still be implicated if the patient’s broader nutritional plan includes plant lipid components or phytosterol-containing materials.
- The “patient is not administered” language pushes the patent beyond “product-only” evaluation and into regimen-level compliance.
Regulatory and product landscape touchpoints (non-exhaustive framing)
US PNALD prevention strategies in practice typically revolve around lipid source composition (soy/plant emulsions vs fish-oil/omega-3 emulsions), plus adjunct regimen choices. This patent specifically aims at the intersection of:
- Fish oil omega-3 lipid emulsions
- Avoidance of phytosterols and plant-derived fatty acids during PN prophylaxis
For competitive positioning, the critical comparisons are:
- fish-oil omega-3 emulsions used for PNALD prevention
- lipid emulsions containing plant-derived components and phytosterols used in total PN
- mixed regimens where more than one lipid source is present
Patent landscape assessment for US 9,629,821 (what to look for and why)
A complete landscape normally requires prosecution history and citation mapping. Based on the claim text supplied, the landscape splits into three competitive clusters.
Cluster 1: Same concept, different formulation
- Fish-oil omega-3 emulsions for PNALD prevention
- Products that can differ on:
- phytosterol content
- plant-derived fatty acid content
- emulsifier chemistry
- marine feedstock source
Risk driver: if they match the “no phytosterols or plant-derived fatty acids” negative limitations at regimen level, claim 1 exposure is higher even without matching dependent emulsifier/fish-source details.
Cluster 2: Same disease target, different lipid strategy
- PNALD prevention using approaches that do not center on fish oil omega-3 emulsions
- Or that use fish oil but keep phytosterols/plant-derived fatty acids in the regimen
Risk driver: avoiding fish oil omega-3 lipid emulsions reduces claim 1 fit. Keeping phytosterols/plant-derived fatty acids in the emulsion or regimen can reduce fit for the negative limitations.
Cluster 3: Patient sub-population and dosing variants
- Infants, premature newborns, short-bowel syndrome, under-2 pediatric methods
- Dosing and duration adaptations
Risk driver: dependent claims (2, 5-10, 12-19, 14, 16) impose narrower constraints. Competitors that clear claim 1 by avoiding fish-oil omega-3 plus negative limitations may still be exposed if they match claim 1 while matching a dependent set.
What the claim set implies about design-around strategies
The patent’s claim architecture indicates design-around options fall into two families: avoid the positive element or break the negative element.
Design-around family A: remove the positive anchor
- Use PNALD prevention approaches not based on fish-oil-derived omega-3 fatty acid lipid emulsions.
- If omega-3 is delivered via non-fish oil sources or via non-emulsion modalities, the fit to “lipid emulsion comprising fish oil derived omega-3” can change.
Design-around family B: keep fish oil but introduce phytosterols/plant-derived fatty acids
- Formulate an emulsion that contains phytosterols or plant-derived fatty acids, or ensure the patient receives them as part of PN.
- Since claim 1 demands the emulsion does not contain those components and the patient is not administered them, introducing either breaks claim fit.
Design-around family C: duration-based or endpoint-based distancing
- Claim 17-19 introduce time windows as dependent limitations.
- A competitor using fish oil omega-3 emulsions for prophylaxis but limiting prophylaxis to periods at or below the thresholds may reduce relevance of those dependent claims (but does not clear claim 1 unless the prophylaxis framing or “preventing PNALD” method proof is also avoided).
Key Takeaways
- US 9,629,821 claim 1 is a method claim for preventing PNALD using an IV fish-oil-derived omega-3 lipid emulsion in long-term total PN regimens, with strict negative limitations: the emulsion has no phytosterols or plant-derived fatty acids, and the patient receives no phytosterols or plant-derived fatty acids.
- Dependent claims narrow on fatty liver disease, marine fish feedstock, specific emulsifiers, pediatric/newborn/short-bowel populations, omega-3 dosing (0.2-3.0 g/kg/day and 0.5-1.0 g/kg/day ranges), and prophylaxis duration (>3 weeks, >6 weeks, >3 months).
- The patent’s highest infringement risk zone is a competitor protocol that uses fish oil omega-3 lipid emulsions for PNALD prevention while the overall PN regimen and lipid selection maintains the no-phytosterol/no-plant-fatty-acid requirement at both product and regimen level.
FAQs
-
Does US 9,629,821 protect a specific fish species?
Claim 3 does, but only as a dependent limitation. Claim 1 broadly requires fish-oil-derived omega-3 fatty acids; dependent claim 3 enumerates specific fish sources.
-
Is the patent limited to infants?
No. Claim 1 covers any human patient receiving long-term total PN. Dependent claims add newborn/infant/pediatric subsets, including a strong under-2 short-bowel syndrome stack in claim 16.
-
What is the most important limitation for clearing the patent?
The two negative regimen limitations: the emulsion must not contain phytosterols or plant-derived fatty acids, and the patient must not be administered phytosterols or plant-derived fatty acids.
-
Do dosing and duration matter for infringement?
Dosing (claims 12-13) and duration (claims 17-19) are dependent limits. Claim 1 can still apply without matching those dependent parameters.
-
Is this a treatment claim or a prevention claim?
It is written as preventing PNALD, which ties infringement analysis to method intent/endpoint in clinical use rather than treating established liver injury.
References
[1] User-provided claim text for “United States Drug Patent 9,629,821” (claims 1-19).
